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ABSTRACT: Treating tuberculosis (TB) patients with inappropriate treatment regimens can lead
to treatment failure and, thus, patients who have not been cured and/or to the development of
(multi)-drug resistance. A systematic review was performed to assess the knowledge of
appropriate TB drug regimens among all categories of healthcare workers (HCWs).
In January 2011, MEDLINE, EMBASE and other databases were searched for relevant articles.
Observational studies published as of the year 2000 that assessed HCW knowledge of TB treatment
wereselected.Atreatmentregimen,drugdosageortreatmentdurationwasconsideredinappropriate
if it was not recommended by national guidelines or by the World Health Organization (WHO).
Of 1,896 studies, 31 were included from 14 different countries. No study was performed in
Europe. In all studies, HCWs with inappropriate knowledge of treatment regimens (8–100%) or
treatment duration (5–99%) were observed. The few studies providing detailed data showed that
HCWs mainly reported giving treatment regimens with too many drugs and for too long.
Knowledge of appropriate doses was also insufficient in most studies.
The available studies show that there is a lack of knowledge of national or international TB
treatment guidelines and recommendations. Generalisation of the findings to other settings and
countries should be done with caution.
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T
reating tuberculosis (TB) patients with in-
appropriate TB treatment regimens, i.e. regi-
mens that are not in accordance with the
World Health Organization (WHO) treatment
guidelines [1–4], can result in the development of
multidrug-resistant (MDR)-TB [5]. A systematic
review published as part of this series in the
EuropeanRespiratoryJournalassessedthepercentage
of TB patients that received an inappropriate
treatment regimen [6]. 37 studies were included.
The studies were from 22 countries, and one study
was from multiple countries. Almost all continents
were represented. In 67% of the studies, inap-
propriate treatment regimens were prescribed. The
percentage of patients receiving inappropriate
regimens ranged between 0.4% and 100%. In 19
studies, detailed information on the treatment
regimen was missing.
The prescription of adequate TB treatment (regi-
men, dosage and duration) requires knowledge of
existing treatment recommendations. Since 1993,
the WHO has published and updated international
TB treatment guidelines [1–4], aiming to provide
national TB programmes (NTPs) and the medical
profession with evidence-based, practical guidance
on effective TB case management. Many countries
have considered and included these recommenda-
tions in their own national TB guidelines. Studies,
oftendescribedasknowledge,attitude and practice
studies, assessing whether these recommendations
are known to individual healthcare workers
(HCWs) have been performed. These studies
commonly measure either the extent of knowledge
about TB treatment among HCWs, or the HCWs’
intended behaviour (‘‘What treatment would you
prescribe for a TB patient?’’).
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treatment regimens prescribed to TB patients [6] and to
investigate a possible cause for inappropriate treatment, we
conducted a systematic review of the literature to specifically
assess the knowledge of appropriate TB drug regimens among
HCWs (i.e. ‘‘do HCWs know what type of drugs, dosage and
durationoftreatmentarerecommendedbynationalguidelinesor
the WHO treatment guidelines?’’). For the purpose of this study,
HCWs are defined as individuals working in public and/or
private healthcare facilities, and those undergoing medical
training (medical students and interns).
METHODS
We followed the Cochrane Handbook for Systematic Reviews [7] and
the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement [8].
Search strategy
To identify relevant studies we conducted a literature search in
the bibliographic databases MEDLINE and EMBASE on January
6, 2011. We also searchedfor guidelines in the National Guideline
Clearinghouse and other guideline databases. Abstracts of
conference proceedings were sought in BIOSIS. Reviews and
guidelines were searched for in the TRIP data base (January/
February 2011).
Keywords used in the search were determined in collaboration
with the clinical librarian of the Dutch Cochrane Centre and
included ‘‘Tuberculosis’’ OR ‘‘TB’’ OR ‘‘Mycobacterium’’ AND
for TB treatment ‘‘Prescriptions’’ OR ‘‘Treatment regimen’’ OR
‘‘Combination treatment’’ OR ‘‘Treatment strategy/-ies’’ OR
‘‘Drug supply’’ OR ‘‘Standard treatment/standard regimen’’
OR ‘‘Inappropriate use, appropriate use, rational use, irrational
use, misuse’’. The search was limited to the publication years
2000–2010 as we were interested in ‘‘current’’ knowledge of
treatment guidelines. We did not limit the search to a
geographical area or countries. Also, we did not use any
languagerestriction. Ifan Englishlanguageabstractwasavailable
thatprovidedthenecessaryinformation,thearticlewasincluded.
We excluded case reports. The searchstrategy was supplemented
by hand searching reference lists of included articles and
identifying relevant review articles.
Selection of studies
We included observational studies among HCWs assessing
knowledge of TB treatment (regimen, dosage, duration) or
intended prescription practices (‘‘What treatment would you
prescribe?’’). For both knowledge and intended prescription
practices, we will use the term ‘‘knowledge’’ in this paper. We
excluded studies that did not report knowledge of the treatment
regimen,dosageortreatmentdurationinsufficientdetailtomake
a judgment on the appropriateness and in which the authors did
not make a statement about appropriateness. Studies identified
by the search strategy were reviewed for eligibility based on title
and abstract by one investigator (M.J. van der Werf). Full
manuscripts of the references selected based on title/abstract
were assessed by one investigator (M.J. van der Werf). For both
steps, a 10% random sample was assessed by a second
investigator (M.W. Langendam) and compared with the assess-
ment of the first reviewer. Inconsistencies in assessment were
discussed and disagreements resolved by consensus. A complete
doubleselection wasplannedif the 10% random samplerevealed
relevant inconsistencies. There were no relevant inconsistencies.
Data extraction
Onereviewer(M.J.vanderWerf)extractedallrelevantdataitems
from the included studies using a data extraction form. This
included the following items: year of publication; country where
study was performed; study setting; aim of the study; period of
data collection; type of HCW; selection method (of respondents);
method of data collection; number of respondents selected/
invited; number of respondents participating; any information
on nonrespondents; characteristics of included HCWs (sex,
age, education, etc.); number of TB cases seen by each HCW
("experience"); intended or observed TB treatment; type of TB
patient for which treatment is reported; TB treatment regimen;
TB treatment dose; TB treatment duration; and prevalence of
inappropriate regimen according to authors. A second reviewer
(M.W. Langendam) checked the extracted results. Inconsistencies
were discussed to obtain consensus.
Data analysis and synthesis of results
The results were summarised qualitatively. For studies describ-
ing treatment regimens reported by HCWs, but without indi-
cating whether they were appropriate according to national or
WHO guidelines, the reported regimens were assessed and
assigned to the appropriate or inappropriate category by the
authors using the WHO treatment guidelines [1–3]. Table 1 lists
the applicable WHO treatment guideline for different periods.
One reviewer assessed the regimens (M.J. van der Werf) and the
otherreviewer(M.W.Langendam)cross-checked theassessment.
The adequacy of knowledge of HCWs on regimen, dose and
duration of TB treatment is summarised. We present results for
HCWs in private settings and in public settings.
RESULTS
Study selection
The search in MEDLINE and EMBASE resulted in 1,896 unique
references. A total of 21 papers were considered relevant (fig. 1).
The National Guideline Clearinghouse, National Institute for
Health and Clinical Excellence (NICE), Scottish Intercollegiate
Guidelines Network (SIGN) and TRIP databases did not provide
aggregated evidence of knowledge of TB treatment by HCWs. In
BIOSIS, 583 references were identified using the keywords
‘‘tuberculosis AND treatment’’ on May 20, 2011. Assessment of
these references did not provide new references.
Checking the reference lists of the included papers revealed 10
relevant studies. Thus, in total, 31 articles were included in the
review. For two studies, only abstracts were available [20, 21].
TABLE 1 Applicability of the different World Health
Organization (WHO) treatment of tuberculosis
guidelines
Period of data
collection
WHO guidelines [Ref.]
1995–1999 First edition: 1993 [1]
1999–2004 Second edition: 1997 [2]
2005–2010 Third edition: 2003 [3]
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The objective of 29 of the 31 included studies was either to assess
knowledge of TB treatment and/or intended practices on TB
treatment, or to assess HCW compliance with the treatment
guidelines. One study’s objective was ‘‘to identify the factors
preventing a better understanding of TB as a social and medical
problem’’ [22] and one study, of which only an abstract was
available, did not specify the objective [21].
The median sample size of the included studies was 114 HCW
(range 22–1,355). The studies were performed in 14 different
countries (table 2), of which 14 (45.2%) were in either India or
Pakistan. Almost all continents were represented: South Asia (15
studies), East and South East Asia (five studies), South West Asia
(four studies), Africa (five studies), the Americas (two studies).
There were no studies from Europe.
A self-administered questionnaire was used in 12 (38.7%) studies
[20, 23, 24, 27, 29–31, 34, 36, 41, 44, 50] and, in 13 (41.9%) studies,
participants were interviewed using a questionnaire [19, 22, 28,
37–40, 43, 45, 46–49]. Four (12.9%) used a questionnaire but did
not specify whether it was performed by interview or was a self-
administered questionnaire [25, 32, 33, 42]. Two studies did not
report how the data were collected [21, 26].
11 (35.5%) studies selected HCWs using random selection
methods [20, 22, 28, 30, 32, 33, 37, 41, 44, 48, 49] and 10 (32.3%)
included all eligible individuals [23, 25, 27, 29, 31, 34, 39, 46, 47,
50]. Six (19.4%) studies used convenience- or purposeful-
sampling, or included HCWs who wanted to participate [24,
35, 36, 38, 40, 45] and four (12.9%) studies did not specify the
selection method [21, 26, 42, 43].
16 (51.6%) studies were performed among HCWs practising in a
private setting [24, 25, 28, 30, 31, 32, 34, 36, 37, 39–41, 44–46, 49],
three (9.7%)among bothHCWs practising in a privatesettingand
in a public setting [29, 47, 48], three (9.7%) among medical
students or interns [20, 21, 27], and nine (29.0%) studies did not
s p e c i f yw h e t h e rt h eH C W sw e r ep r a c t i s i n gi nap r i v a t eo rp u b l i c
setting [22, 23, 26, 33, 35, 38, 42, 43, 50] (table 3).
Prevalence of inappropriate knowledge of TB treatment
The percentage of HCWs with inappropriate knowledge of TB
regimens in the studiesamong private providers rangedbetween
20% and 100% (median 74%; table 3); in one study the level was
reported as .41% [39]. The level of inappropriate knowledge of
treatment regimens ranged between 8% and 93% (median 73%)
among HCWs practising in settings other than uniquely private.
Three studies did not provide the data to assess the percentage
[22, 29, 42], in one study it was ,25% [26] and in another study
.55% [27].
15 studies provided information on HCWs experience in treating
TB patients [25, 30, 31–34, 36, 38–40, 42, 46–48, 50]. In the 10
studies where o80% of the HCWs managed TB cases, or where
the average number of TB cases managed per HCW was at least
five per month, 8% to 100% had inappropriate knowledge of the
recommended treatment regimen (median 61.5) [25, 30–34, 38, 39,
48, 50].
Six studies provided data that allowed assessing whether HCWs’
knowledge on the number of different drugs required in a TB
treatment regimen was adequate, or whether they would
prescribe too many or too few drugs. Three studies specifically
reported on HCWs practising in a private setting. AUER et al.[ 3 9 ]
reported that nine (20%) out of 45 private practitioners would
prescribe fewer than four drugs in the intensive phase for far-
advanced TB; this is 22% of all inappropriate answers reported in
the study. KHAN et al. [34] reported that 10 out of 120 private
physicianswouldprescribe fewer thanfour drugs in the intensive
phase for pulmonary TB, i.e. 63% of all reported inappropriate
treatment in the intensive phase. In another study, 2% of private
practitioners would prescribe three drugs for sputum-positive
pulmonary TB [25], whereas 18% would prescribe an inappropri-
ate regimen of four or five drugs.
Three studies among HCWs for which the setting was not
specified provided information about prescription of more or less
than four drugs during the intensive phase. CIRIT et al.[ 4 3 ]
reported that 98 (60%) out of 162 physicians prescribed fewer
than four drugs for newly diagnosed TB. Of 84 family physicians
with an interpretable answer in the study by RIZVI et al.[ 3 3 ] ,2 0
(25%) would prescribe a one-, two- or three-drug regimen for
Identified from MEDLINE, EMBASE
and other databases:
1896 references
References retained for review for
full manuscript: 32
References included: 21
Total number of references: 31
10 references included 
from reference 
list 
11 references excluded based 
on evaluation of full 
manuscript:
  4 insufficient treatment
     regimen detail
  3 patient data insufficient
  2 pharmacy-dispensing
    information insufficient
  2 not measuring knowledge
1864 references excluded based 
on title and abstract:
  830 not about tuberculosis
  84 about latent tuberculosis
  473 had no observational study
  185 included no treatment
  292 not about healthcare
    workers
FIGURE 1. Summary of literature search and study selection. References were
excluded based on evaluation of the full manuscript according to: treatment
regimen given in insufficient detail [9–12]; level of patient data insufficient [13–15];
insufficient pharmacy dispensing information [16, 17]; and not measuring knowl-
edge [18, 19].
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First author [ref.] Country Study
setting
Period of data
collection
Type of HCW Sample size n
South Asia
AGARWAL [23] India Conference 2006 National and international orthopaedic faculty and infectious
disease experts
52
ROY [24] India Municipal area NR Qualified private medical practitioners 55
UDWADIA [25] India Slum NR Private medical practitioners 106
BHALLA [26] India Medical institute NR Residents and faculty members from various departments 40
RAJPAL [27] India Medical schools 2002 Interns that had gone through their training in various
disciplines of medicine
287
GREAVES [28] India City and
surrounding
area
2006 Private practitioners 45
VANDAN [29] India District 2007 Medical physicians (public and private) 141
DATTA [30] India District 2008 Private allopathic physicians 260
HURTIG [31] Nepal Municipality 1998 Licensed allopathic for profit private practitioners which were
assumed to see TB patients
43
SHAH [32] Pakistan Large cities NR Formally qualified medical graduates who were practising
medicine outside the government sector and who had
managed at least one pulmonary TB patient during the
previous year
245
RIZVI [33] Pakistan City NR Family physicians that had no postgraduate qualification and
were treating at least 7–10 TB patients per month
150
KHAN [21] Pakistan Teaching hospitals NR Interns 440
KHAN [34] Pakistan City 2002 Qualified private practitioners 120
SHEHZADI [35] Pakistan Regions 2003 General practitioners 88
AHMED [36] Pakistan Rural district 2007 Private practitioners with basic medical degree and doing
private practice for o1y r
22
East and South East Asia
BAI [20] China Medical schools NR Final year medical students 439
MAHENDRADHATA [37] Indonesia City 2004 Private practitioners 164
YU [38] Philippines Tertiary care hospital NR Specialist physicians who dealt with pulmonary TB patients 38
AUER [39] Philippines Urban district
(Metro Manilla)
1999–2000 Private for-profit practitioners who treat TB 45
PORTERO [40] Philippines Country 2001 Private physicians 1355
South West Asia
SHIRZADI [41] Iran Large cities 2001–2002 Private sector physicians 732
HASHIM [22] Iraq Public health
centres in the
country
2001–2002 HCWs 500
DEVECI [42] Turkey City NR Practising physicians who provide first-line treatment 66
CIRIT [43] Turkey City 2001 Physicians 208
Africa
SHIMELES [44] Ethiopia City 2003 Private, for-profit medical doctors 120
AYAYA [45] Kenya Cosmopolitan town NR Medical doctors practising privately 53
CHAKAYA [46] Kenya Slum 2001 Private HCWs 75
SULEIMAN [47] Somalia Part of country 2001 Qualified medical practitioners (public and private sector) 53
NSHUTI [48] Uganda Urban district 1999 Doctor or medical assistant from public and private clinics 114
Americas
DATO [49] Argentina City 2007 Private doctors: general practitioners, infectious disease
specialists and pulmonologists
61
LOBUE [50] USA County NR Physicians who reported a TB suspect or case to the San
Diego County Tuberculosis Control for the years 1995–1997
150
HCW: healthcare worker; NR: not reported; TB: tuberculosis.
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r e g i m e no fm o r et h a nf o u rd r u g s .Y U et al.[ 3 8 ]r e p o r t e dt h a ta l l
HCWs reporting an inappropriate prescription (8%) would
prescribe a three-drug regimen for pulmonary TB [38].
Six studies reported on the knowledge of TB drug-dose in
regimens (table 3) [23, 26, 29, 34, 39, 41]. One study reported all
mentioned doses as adequate [23]. Two studies reported that 46%
[41] and 50% [26] of the HCWs would prescribe an incorrect dose
(eithertoolowor too high). Three studiesreported on knowledge
of dose by individual drug (table 4) [29, 34, 39]. In two studies,
high doses were more frequently mentioned [34, 39] than low
doses for most drugs and, in one study, participants would more
frequently prescribe low doses of isoniazid, pyrazinamide and
ethambutol [29]. For rifampicin, the participants would more
frequently prescribe high doses.
Knowledge of the duration of treatment regimens was reported in
13 studies [22, 25, 27, 29, 31–33, 38, 41–43, 49, 50]. Between 1% and
95% of the HCWs knew the correct duration of treatment. Overall,
only a few HCWs would prescribe a regimen that was too short
(,6 months): 3% [31]; 8% [25]; 11% [27]; 52% [43]; 4% [22]; and
none in the studies reported by RIZVI et al.[ 3 3 ]a n dY U et al.[ 3 8 ] .
DISCUSSION
The studies included in this systematic review show that a
large proportion of HCWs do not know or do not intend to
TABLE 3 Prevalence of inappropriate tuberculosis (TB) regimens, incorrect dose and incorrect duration of TB treatment in
different types of healthcare workers (HCWs)
First author [ref.] Prevalence %
Inappropriate regimen Incorrect dose Incorrect duration
HCWs in private setting
AHMED [36] .41
AUER [39] 91 Rifampicin 9, isoniazid 84,
pyrazinamide 88, ethambutol 57
AYAYA [45] 77
CHAKAYA [46] 92
DATO [47] 22 33
DATTA [30] 79
GREAVES [28] 58
HURTIG [31] 49 31
KHAN [34] 74 Rifampicin 24, isoniazid 17,
pyrazinamide 48, ethambutol 49
Rifampicin 50, isoniazid 48,
pyrazinamide 39, ethambutol 47
MAHENDRADHATA [37] 73
PORTERO [40] 89
ROY [24] 70
SHAH [32] 100 99
SHIMELES [44] 90
SHIRZADI [41] 66 46 50
UDWADIA [25] 20 64
HCWs in public and private setting
NSHUTI [48] 76
SULEIMAN [47] 93
VANDAN [29] No data Rifampicin 22, isoniazid 78,
pyrazinamide 47, ethambutol 72
16
Medical students or interns
BAI [20] 83
KHAN [21] 48
RAJPAL [27] .55 70
HCWs setting not specified
AGARWAL [23] 81 0
BHALLA [26] ,25 50
CIRIT [43] 81 65
DEVECI [42] No data 52
HASHIM [22] No data 13
LOBUE [50] 11 26
RIZVI [33] 33 87
SHEHZADI [35] 70
YU [38] 8 5
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international guidelines.
Treatment with too few drugs and for a too short duration has
been shown to result in ineffective treatment outcomes of
patients. Specifically, patients treated with regimens in which
rifampicin is only given for the first 1 to 2 months, i.e. only used
in the intensive treatment phase, have significantly worse
treatment outcomes compared with regimens with rifampicin
throughout therapy. Furthermore, these patients have an
increased risk of acquiring rifampicin resistance [51]. It has also
been shown that treatment with fewer than four drugs in the
intensive phase results in higherpercentages of relapse cases [52].
It is on this basis that, for new pulmonary TB patients, WHO
guidelines recommend a regimen containing isoniazid, rifampi-
cin, pyrazinamide and ethambutol in the 2-month intensive
treatment phase, and isoniazid and rifampicin in the 4-month
continuation treatment phase [4]. The studies observed in this
review, in which HCWs reported prescribing too few drugs, are
therefore of concern, both for the treatment outcome of patients
and fortherisk ofresistancedevelopment.Threestudies,without
a specifiedsetting (private or public), reporteda higher frequency
of treatment with fewer than four drugs compared with
treatment with more than four drugs [33, 38, 43].
A known cause of treatment default is the burden of drug side-
effects to patients [53, 54]. Three studies among HCWs practising
in a private setting reported a higher frequency of treatment with
too many drugs among this group of HCWs [34, 39, 25]. While it is
essential to treat TB with the recommended number of drugs and
for the correct duration, due to the side-effects caused by several
drugs(especially in HIV-infected TB patients), the useof too many
drugs should be avoided [55–57]. This is further supported by the
knowledge that treatment with an increased number of drugs,
such as the treatment of MDR-TB, is known to cause a higher
frequency of side-effects [58] and is a known cause of default from
treatment [53, 54]. Based on this, prescribing more drugs than
officially recommended should be discouraged so as to reduce
development of side-effects and, thus, default from treatment.
For most drugs, the occurrence of side-effects is dose dependent
[59] and, thus, prescribing a higher dose will give a higher chance
of side-effects. In the three studies providing information on
intendedprescription ofhighdoses[29,34,39],therewasnoclear
tendency for excessive doses to be more frequently prescribed
than insufficient doses.
It should be noted that the included study populations in the
identified studies might not be representative of all public and
private HCWs. For example, none ofthe 31 includedstudies were
from Europe. Also, India and Pakistan were highly over-
represented, with almost half of the 31 studies set in these two
countries alone. Conversely, most of the studies either used
random selection or included the complete target population,
indicating that the participating HCWs should be representative
of the target population.
In a separate study published in this series of the European
Respiratory Journal, we assessed the prevalence of inappropriate
TB treatment in populations of TB patients [6] and observed that,
in 67% of the included studies, inappropriate regimens were
prescribed.In the current article,all theincluded studiesreported
on HCWs’ knowledge of TB regimens, and all showed a lack of
knowledge among the different groups of HCWs. Even among
the 10 studies on HCWs with experience in managing TB
patients, knowledge was insufficient [25, 30–34, 38, 39, 48, 50].
Although the HCW study population in the current study does
not link specifically to the settings in our assessment of
prevalence of inappropriate treatment [6], the lack of knowledge
among HCWs is a suggestive cause for the prevalence of
inappropriate treatment regimens. In other words, if knowledge
of appropriate TB regimens is insufficient, the actual prescription
is most likely to also be insufficient. Indeed, a previous study
assessingwhichTBtreatmentwasactually prescribed by primary
doctorsshowedthat75%madeprescriptionerrorswithrespectto
o n eo rm o r ea s p e c t so ft r e a t m e n t .T h i si n c l u d e de r r o r si n
treatment regimen (45.2%), treatment duration (64.5%) and drug
dosages (30%) [18]. In another study, in which a simulation
patient was used, only two (3.7%) prescriptions out of 53 met the
required standards for TB patients as defined by the NTP [19].
These two studies measuring the actual practices are in line with
the studies assessing HCW knowledge.
TB treatment consists of different treatment modalities: regimen;
dose; frequency; and duration. Most of the 31 included studies
provided information on treatment regimen (91%, n530), only a
fewstudiesprovidedinformationondose(19%,n56) or duration
of the treatment regimen (42%, n513), and none of the studies
provided information on the frequency of treatment (i.e. daily,
thriceweekly,twiceweekly,etc.). The adequacyof the knowledge
of TB treatment could therefore only be assessed to a limited
extent.
Unpublished studies cannot be found with a systematic review
search strategy and were thus not included in our search
strategies. It is possible that studies recording mainly adequate
knowledge of treatment regimens are less frequently published
than studies that measure and report on inadequate knowledge.
If this is the case, overall knowledge of HCWs on TB treatment
m i g h tb eb e t t e rc o m p a r e dt ow h a tw er e p o r th e r e i n .
10 out of the 31 studies included in our systematic review were
identified by reviewing the references of included studies. These
10 studies did not contain the keywords that we used in our search
strategy with regard to thetitle, abstract or keywords section. They
did, however, contain the words ‘‘treatment’’ or ‘‘therapy’’ in the
title or abstract. As the words ‘‘treatment’’ or ‘‘therapy’’ are not
TABLE 4 Percentage of healthcare workers that reported
an inadequate dose for the four first-line drugs
in three studies providing information
Drug AUER [39] KHAN [34] VANDAN [29]
Too
low
Too
high
Too
low
Too
high
Too
low
Too
high
Rifampicin 1 (2) 3 (7) 20 (20) 5 (4) 0 (0) 28 (22)
Isoniazid 2 (4) 36 (80) 6 (6) 13 (11) 98 (75) 3 (2)
Pyrazinamide 2( 5 )
# 35 (83)
# 15 (15) 40 (33) 43 (33) 18 (14)
Ethambutol 10 (33)
" 7 (23)
" 10 (10) 47 (39) 83 (64) 11 (8)
Data are presented as n (%).
#: 42 instead of 45 participants;
": 30 instead of 45
participants.
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did not include them in our search strategy. With our search
strategy and careful examination of the included studies’
references, we believe that the majority of relevant published
manuscripts on HCWs’ knowledge of treatment were identified.
Conclusion
The available studies in this systematic review show that there is
a lack of knowledge of the national or international guidelines
and recommendations for TB treatment. Generalisation of the
findings to other settings and countries should be done with
caution.
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